Several HDAC inhibitors (HDACis), such as vorinostat, romidepsin, and belinostat, have received approval for the treatment of cutaneous T-cell lymphoma or peripheral T-cell lymphoma, with pracinostat also being granted orphan drug status for the treatment of AML [17, 18]. Here, HDAC9 is linked to acute myeloid leukemia.